World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
113
Citations
49220
World Ranking
4935
National Ranking
2675

Ola Landgren publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ola Landgren sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 784 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ola Landgren D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ola Landgren sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 113 D-Index — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ola Landgren is affiliated with the University of Miami in the United States and has contributed extensively to research in medicine, particularly focusing on hematology and molecular biology. Their research encompasses oncology, genetics, and cancer research, with a pronounced emphasis on multiple myeloma.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Subfields prominently featured in their work consist of:

  • Hematology
  • Molecular Biology
  • Oncology
  • Genetics
  • Cancer Research

The key research topics covered by Ola Landgren's publications are:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Cancer Genomics and Diagnostics
  • Chronic Lymphocytic Leukemia Research
  • Peptidase Inhibition and Analysis
  • Cancer Treatment and Pharmacology
  • CAR-T cell therapy research

Several recent papers authored or co-authored by Ola Landgren illustrate their scientific focus and contribution to multiple myeloma and related therapies:

  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study, 2020, The Lancet
  • GPRC5D-Targeted CAR T Cells for Myeloma, 2022, New England Journal of Medicine
  • Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma, 2023, Nature Medicine
  • Timing the initiation of multiple myeloma, 2020, Nature Communications
  • The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma, 2021, Nature Communications

Ola Landgren collaborates frequently with other researchers, particularly:

  • Francesco Maura
  • Malin Hultcrantz
  • Benjamin Diamond
  • Kylee Maclachlan
  • Alexander M. Lesokhin

The specialist often publishes in venues that include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Blood Cancer Journal
  • Blood Cancer Discovery

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study

    Ola Landgren;Robert A. Kyle;Ruth M. Pfeiffer;Jerry A. Katzmann

  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    R A Kyle;B G M Durie;S V Rajkumar;O Landgren

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

  • Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.

    Cecilie Blimark;Erik Holmberg;Ulf-Henrik Mellqvist;Ola Landgren

  • Solid cancers after allogeneic hematopoietic cell transplantation

    J. Douglas Rizzo;Rochelle E. Curtis;Gérard Socié;Kathleen A. Sobocinski

  • Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation

    Ola Landgren;Ethel S. Gilbert;J. Douglas Rizzo;Gérard Socié

  • B-cell clones as early markers for chronic lymphocytic leukemia.

    Ola Landgren;Maher Albitar;Wanlong Ma;Fatima Abbasi

  • International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

    Antonio Palumbo;S. Vincent Rajkumar;Jesus F. San Miguel;Alessandra Larocca

  • Racial disparities in incidence and outcome in multiple myeloma: a population-based study

    Adam J. Waxman;Pamela J. Mink;Susan S. Devesa;William F. Anderson

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    C. Fernández De Larrea;R. A. Kyle;B. G.M. Durie;H. Ludwig

  • Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus

    Thomas P. Giordano;Louise Henderson;Louise Henderson;Ola Landgren;Elizabeth Y. Chiao;Elizabeth Y. Chiao

  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.

    Meletios Dimopoulos;Hang Quach;Maria-Victoria Mateos;Ola Landgren

  • Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans

    Hashem B. El-Serag;Hashem B. El-Serag;Eric A. Engels;Ola Landgren;Elizabeth Chiao;Elizabeth Chiao

  • Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States

    Ola Landgren;Gloria Gridley;Ingemar Turesson;Neil E. Caporaso

  • Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003

    Sigurdur Yngvi Kristinsson;Ola Landgren;Paul W. Dickman;Åsa Rangert Derolf

  • Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up

    Sigurdur Y. Kristinsson;Gloria Gridley;Robert N Hoover;David Check

  • Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

    Neha Korde;Neha Korde;Mark Roschewski;Adriana Zingone;Mary Kwok

  • Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

    Ola Landgren;Ola Landgren;Lynn R. Goldin;Sigurdur Y. Kristinsson;Elin A. Helgadottir

Frequent Co-Authors

Magnus Björkholm
Magnus Björkholm Karolinska University Hospital
Lynn R. Goldin
Lynn R. Goldin National Institutes of Health
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Maryalice Stetler-Stevenson
Maryalice Stetler-Stevenson National Institutes of Health
Neil E. Caporaso
Neil E. Caporaso National Institutes of Health
Ruth M. Pfeiffer
Ruth M. Pfeiffer National Institutes of Health
Ahmet Dogan
Ahmet Dogan Memorial Sloan Kettering Cancer Center
Gloria Gridley
Gloria Gridley National Institutes of Health
Eric A. Engels
Eric A. Engels National Institutes of Health
Robert A. Kyle
Robert A. Kyle Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in alternative career paths in healthcare or looking to further their education online, numerous flexible options are available. Advanced nursing programs, for example, allow medical professionals to broaden their expertise and credentials. If you're seeking the quickest way to an advanced degree, consider the shortest dnp program online to fast-track your doctorate in nursing practice.

Some students pursue accelerated formats, such as a 1 year dnp program online, balancing intensive study with work and family commitments. Those looking to start a nursing career even faster may be interested in the 6 month lpn program, which offers entry into the workforce with minimal delay.

Many specialties are also available, including mental health. Aspiring nurse practitioners can explore online pmhnp programs, preparing for advanced practice in psychiatric nursing—a growing field in the U.S. These online pathways provide flexible, reputable options for both new and experienced healthcare professionals.

Best Scientists Citing Ola Landgren

Trending Scientists